Advances in emerging therapies 2009.

Advances in Stroke Advances in Emerging Therapies 2009

Prospects for control of emerging infectious diseases with plasmid DNA vaccines

Experiments almost 20 years ago demonstrated that injections of a sequence of DNA encoding part of a pathogen could stimulate immunity. It was soon realized that "DNA vaccination" had numerous potential advantages over conventional vaccine approaches including inherent safety and a more rapid production time. These and other attributes make DNA vaccines ideal for development against emerging pa...

O19: Advances in the Treatment and Limitations of Cell Therapy in Neurodegenerative Diseases

Neurodegenerative diseases are the hereditary and sporadic diseases which are characterized by progressive neuronal loss of the nervous system and are emerging as the leading cause of death, disabilities, and a socioeconomic burden due to an increase in life expectancy. There are many neurodegenerative diseases including Alzheimer’s disease, Parkinson’s, disease, amyotrophic lateral...

Emerging Drug Therapies for Heart Failure

Heart failure is associated with high morbidity and mortality and is proving to be an economic burden in developing countries. A number of therapeutic agents are presently employed in heart failure; but they are not sufficient to control symptoms of heart failure. Moreover, the prevalence of chronic heart failure is progressively increasing and thus there is a continuing need to develop effecti...

Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies

Over the last few decades, advances in immunochemotherapy have led to dramatic improvement in the prognosis of non-Hodgkin's lymphoma (NHL). Despite these advances, relapsed and refractory disease represents a major treatment challenge. For both aggressive and indolent subtypes of NHL, there is no standard of care for salvage regimens, with prognosis after relapse remaining relatively poor. Nev...